The London and Cambridge Life Sciences Team advised Morningside on its lead investment into ieso, as part of a $53m Series B funding round which included investments from Sony Innovation Fund, IP Group, Molten Ventures and Ananda Impact Ventures.
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility.
ieso is a UK-based digital mental healthcare firm that provides an advanced AI-driven digital therapeutics platform aimed at addressing the global mental health crisis.
For more information please visit ieso.